BUSCOPAN 20 MG
HYOSCINE BUTYLBROMIDE : 20 MG · DIN 00363839 · SANOFI CONSUMER HEALTH INC
Health Canada status: MARKETED
What is BUSCOPAN?
BUSCOPAN 20 MG contains HYOSCINE BUTYLBROMIDE : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 00363839, held by SANOFI CONSUMER HEALTH INC, supplied as SOLUTION for SUBCUTANEOUS ; INTRAVENOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 16-Aug-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BUSCOPAN used for?
BUSCOPAN (hyoscine butylbromide) tablets are indicated for: The relief of smooth muscle spasm/cramping of the gastrointestinal system and its associated pain and discomfort. BUSCOPAN solution is indicated for: The relief of acute genitourinary or gastrointestinal spasm (e.g., renal or biliary colic), or to produce smooth muscle relaxation prior to radiological procedures such as pyelography or other diagnostic procedures where spasm may be a problem (e.g., gastro-duodenal endoscopy).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00363839 |
|---|---|
| Brand name | BUSCOPAN |
| Generic / active ingredient | HYOSCINE BUTYLBROMIDE : 20 MG |
| Manufacturer | SANOFI CONSUMER HEALTH INC |
| Strength | 20 MG |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS ; INTRAVENOUS ; INTRAMUSCULAR |
| Schedule | Prescription |
| ATC code | A03BB01 BUTYLSCOPOLAMINE |
| AHFS class | 28:08.12 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 16-Aug-2022 |
| Original market date | 1930-12-31 00:00:00 |
How is it stored and handled?
BUSCOPAN tablets and solution should be protected from light and heat. BUSCOPAN solution should be protected from freezing. Products should be stored at 15 – 30°C and are stable up to the expiration date indicated on the label.
How is it supplied?
Tablets: Blister packages of 10 and 20 tablets. Formats of 10, 20, 40. Solution: Packages of 10 ampoules.
What can be used instead?
Other Canadian products sharing ATC code A03BB01 BUTYLSCOPOLAMINE. 5 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACCEL-HYOSCINE | 10 MG | TABLET | ACCEL PHARMA INC | MARKETED | DIN 02512335 |
| BUSCOPAN | 10 MG | TABLET | SANOFI CONSUMER HEALTH INC | MARKETED | DIN 00363812 |
| HYOSCINE BUTYLBROMIDE INJECTION | 20 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02229868 |
| HYOSCINE BUTYLBROMIDE INJECTION BP | 20 MG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 02508419 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.